{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:11:17Z","timestamp":1787065877818,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T00:00:00Z","timestamp":1543363200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T00:00:00Z","timestamp":1543363200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100001445","name":"Alex\u2019s Lemonade Stand Foundation for Childhood Cancer","doi-asserted-by":"publisher","award":["Developmental Therapeutics Center of Excellence Program"],"award-info":[{"award-number":["Developmental Therapeutics Center of Excellence Program"]}],"id":[{"id":"10.13039\/100001445","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA125123"],"award-info":[{"award-number":["CA125123"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Curing Kids Cancer","award":["Killian Owen Fellowship in Developmental Therapeutics"],"award-info":[{"award-number":["Killian Owen Fellowship in Developmental Therapeutics"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s00280-018-3733-2","type":"journal-article","created":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T01:01:48Z","timestamp":1543366908000},"page":"349-360","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["A prospective study of a simple algorithm to individually dose high-dose methotrexate for children with leukemia at risk for methotrexate toxicities"],"prefix":"10.1007","volume":"83","author":[{"given":"Jennifer H.","family":"Foster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick A.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Brooke","family":"Bernhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith F.","family":"Margolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan G.","family":"Hilsenbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunji","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah A.","family":"Marquez-Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Scheurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7063-512X","authenticated-orcid":false,"given":"Eric S.","family":"Schafer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,28]]},"reference":[{"issue":"12","key":"3733_CR1","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1016\/j.ejca.2014.04.014","volume":"50","author":"A Paci","year":"2014","unstructured":"Paci A, Veal G, Bardin C, Leveque D, Widmer N, Beijnen J, Astier A, Chatelut E (2014) Review of therapeutic drug monitoring of anticancer drugs part 1\u2014cytotoxics. Eur J Cancer 50(12):2010\u20132019. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2014.04.014","journal-title":"Eur J Cancer"},{"issue":"4","key":"3733_CR2","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1182\/blood-2010-06-292615","volume":"118","author":"BL Asselin","year":"2011","unstructured":"Asselin BL, Devidas M, Wang C, Pullen J, Borowitz MJ, Hutchison R, Lipshultz SE, Camitta BM (2011) Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children\u2019s Oncology Group (POG 9404). Blood 118(4):874\u2013883. \n                    https:\/\/doi.org\/10.1182\/blood-2010-06-292615","journal-title":"Blood"},{"issue":"20","key":"3733_CR3","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1200\/JCO.2015.62.4544","volume":"34","author":"EC Larsen","year":"2016","unstructured":"Larsen EC, Devidas M, Chen S, Salzer WL, Raetz EA, Loh ML, Mattano LA Jr, Cole C, Eicher A, Haugan M, Sorenson M, Heerema NA, Carroll AA, Gastier-Foster JM, Borowitz MJ, Wood BL, Willman CL, Winick NJ, Hunger SP, Carroll WL (2016) Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from children\u2019s oncology group study AALL0232. J Clin Oncol 34(20):2380\u20132388. \n                    https:\/\/doi.org\/10.1200\/JCO.2015.62.4544","journal-title":"J Clin Oncol"},{"issue":"1","key":"3733_CR4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/pbc.10392","volume":"42","author":"PC Nathan","year":"2004","unstructured":"Nathan PC, Maze R, Spiegler B, Greenberg ML, Weitzman S, Hitzler JK (2004) CNS-directed therapy in young children with T-lineage acute lymphoblastic leukemia: high-dose methotrexate versus cranial irradiation. Pediatr blood cancer 42(1):24\u201329. \n                    https:\/\/doi.org\/10.1002\/pbc.10392","journal-title":"Pediatr blood cancer"},{"issue":"10","key":"3733_CR5","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1182\/blood.V78.10.2514.2514","volume":"78","author":"CM Niemeyer","year":"1991","unstructured":"Niemeyer CM, Gelber RD, Tarbell NJ, Donnelly M, Clavell LA, Blattner SR, Donahue K, Cohen HJ, Sallan SE (1991) Low-dose versus high-dose methotrexate during remission induction in childhood acute lymphoblastic leukemia (protocol 81-01 update). Blood 78(10):2514\u20132519","journal-title":"Blood"},{"issue":"1","key":"3733_CR6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I","volume":"41","author":"WA Bleyer","year":"1978","unstructured":"Bleyer WA (1978) The clinical pharmacology of methotrexate: new applications of an old drug. Cancer 41(1):36\u201351","journal-title":"Cancer"},{"issue":"5","key":"3733_CR7","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/j.1365-2141.2009.07765.x","volume":"146","author":"K Schmiegelow","year":"2009","unstructured":"Schmiegelow K (2009) Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol 146(5):489\u2013503. \n                    https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07765.x","journal-title":"Br J Haematol"},{"issue":"6","key":"3733_CR8","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1634\/theoncologist.11-6-694","volume":"11","author":"BC Widemann","year":"2006","unstructured":"Widemann BC, Adamson PC (2006) Understanding and managing methotrexate nephrotoxicity. The Oncologist 11(6):694\u2013703. \n                    https:\/\/doi.org\/10.1634\/theoncologist.11-6-694","journal-title":"The Oncologist"},{"issue":"12","key":"3733_CR9","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","volume":"21","author":"SC Howard","year":"2016","unstructured":"Howard SC, McCormick J, Pui CH, Buddington RK, Harvey RD (2016) Preventing and managing toxicities of high-dose methotrexate. The Oncologist 21(12):1471\u20131482. \n                    https:\/\/doi.org\/10.1634\/theoncologist.2015-0164","journal-title":"The Oncologist"},{"issue":"2","key":"3733_CR10","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/pbc.24623","volume":"61","author":"TS Mikkelsen","year":"2014","unstructured":"Mikkelsen TS, Mamoudou AD, Tuckuviene R, Wehner PS, Schroeder H (2014) Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study. Pediatr Blood Cancer 61(2):297\u2013301. \n                    https:\/\/doi.org\/10.1002\/pbc.24623","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"3733_CR11","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1002\/cncr.20255","volume":"100","author":"BC Widemann","year":"2004","unstructured":"Widemann BC, Balis FM, Kempf-Bielack B, Bielack S, Pratt CB, Ferrari S, Bacci G, Craft AW, Adamson PC (2004) High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer 100(10):2222\u20132232. \n                    https:\/\/doi.org\/10.1002\/cncr.20255","journal-title":"Cancer"},{"issue":"4","key":"3733_CR12","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/ndt\/gfw456","volume":"32","author":"J Bouchard","year":"2017","unstructured":"Bouchard J, Lavergne V, Roberts DM, Cormier M, Morissette G, Ghannoum M (2017) Availability and cost of extracorporeal treatments for poisonings and other emergency indications: a worldwide survey. Nephrol Dial Transp 32(4):699\u2013706. \n                    https:\/\/doi.org\/10.1093\/ndt\/gfw456","journal-title":"Nephrol Dial Transp"},{"issue":"5","key":"3733_CR13","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/1097-0142(19880901)62:5<884::AID-CNCR2820620506>3.0.CO;2-A","volume":"62","author":"MV Relling","year":"1988","unstructured":"Relling MV, Stapleton FB, Ochs J, Jones DP, Meyer W, Wainer IW, Crom WR, McKay CP, Evans WE (1988) Removal of methotrexate, leucovorin, and their metabolites by combined hemodialysis and hemoperfusion. Cancer 62(5):884\u2013888","journal-title":"Cancer"},{"issue":"6","key":"3733_CR14","doi-asserted-by":"publisher","first-page":"R184","DOI":"10.1186\/cc8172","volume":"13","author":"MJ Santiago","year":"2009","unstructured":"Santiago MJ, Lopez-Herce J, Urbano J, Solana MJ, del Castillo J, Ballestero Y, Botran M, Bellon JM (2009) Complications of continuous renal replacement therapy in critically ill children: a prospective observational evaluation study. Crit Care 13(6):R184. \n                    https:\/\/doi.org\/10.1186\/cc8172","journal-title":"Crit Care"},{"key":"3733_CR15","unstructured":"VORAXAZE(R) (glucarpidase) [package insert] (2017) BTG International, Inc. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/125327lbl.pdf\n                    \n                  . Accessed Jul 2018"},{"issue":"1","key":"3733_CR16","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1517\/14712590903468677","volume":"10","author":"DM Patterson","year":"2010","unstructured":"Patterson DM, Lee SM (2010) Glucarpidase following high-dose methotrexate: update on development. Expert Opin Biol Ther 10(1):105\u2013111. \n                    https:\/\/doi.org\/10.1517\/14712590903468677","journal-title":"Expert Opin Biol Ther"},{"issue":"25","key":"3733_CR17","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1200\/JCO.2009.25.4540","volume":"28","author":"BC Widemann","year":"2010","unstructured":"Widemann BC, Balis FM, Kim A, Boron M, Jayaprakash N, Shalabi A, O\u2019Brien M, Eby M, Cole DE, Murphy RF, Fox E, Ivy P, Adamson PC (2010) Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome. J Clin Oncol 28(25):3979\u20133986. \n                    https:\/\/doi.org\/10.1200\/JCO.2009.25.4540","journal-title":"J Clin Oncol"},{"issue":"9","key":"3733_CR18","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1002\/pbc.25395","volume":"62","author":"JR Scott","year":"2015","unstructured":"Scott JR, Zhou Y, Cheng C, Ward DA, Swanson HD, Molinelli AR, Stewart CF, Navid F, Jeha S, Relling MV, Crews KR (2015) Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients. Pediatr Blood Cancer 62(9):1518\u20131522. \n                    https:\/\/doi.org\/10.1002\/pbc.25395","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"3733_CR19","doi-asserted-by":"publisher","first-page":"E40","DOI":"10.1002\/ajh.24969","volume":"93","author":"ES Schafer","year":"2018","unstructured":"Schafer ES, Bernhardt MB, Reichert KE, Haworth TE, Shah MD (2018) Hispanic ethnicity as a risk factor for requiring glucarpidase rescue in pediatric patients receiving high-dose methotrexate. Am J Hematol 93(2):E40\u2013E42. \n                    https:\/\/doi.org\/10.1002\/ajh.24969","journal-title":"Am J Hematol"},{"issue":"5","key":"3733_CR20","first-page":"797","volume":"61","author":"H Chan","year":"1977","unstructured":"Chan H, Evans WE, Pratt CB (1977) Recovery from toxicity associated with high-dose methotrexate: prognostic factors. Cancer Treat Rep 61(5):797\u2013804","journal-title":"Cancer Treat Rep"},{"issue":"8","key":"3733_CR21","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1200\/JCO.1994.12.8.1667","volume":"12","author":"MV Relling","year":"1994","unstructured":"Relling MV, Fairclough D, Ayers D, Crom WR, Rodman JH, Pui CH, Evans WE (1994) Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol 12(8):1667\u20131672. \n                    https:\/\/doi.org\/10.1200\/JCO.1994.12.8.1667","journal-title":"J Clin Oncol"},{"issue":"8","key":"3733_CR22","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1056\/NEJM198602203140803","volume":"314","author":"WE Evans","year":"1986","unstructured":"Evans WE, Crom WR, Abromowitch M, Dodge R, Look AT, Bowman WP, George SL, Pui CH (1986) Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med 314(8):471\u2013477. \n                    https:\/\/doi.org\/10.1056\/NEJM198602203140803","journal-title":"N Engl J Med"},{"issue":"4","key":"3733_CR23","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/pbc.23074","volume":"57","author":"E Lopez-Lopez","year":"2011","unstructured":"Lopez-Lopez E, Martin-Guerrero I, Ballesteros J, Pinan MA, Garcia-Miguel P, Navajas A, Garcia-Orad A (2011) Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 57(4):612\u2013619. \n                    https:\/\/doi.org\/10.1002\/pbc.23074","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"3733_CR24","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s00280-013-2206-x","volume":"72","author":"JL Pauley","year":"2013","unstructured":"Pauley JL, Panetta JC, Crews KR, Pei D, Cheng C, McCormick J, Howard SC, Sandlund JT, Jeha S, Ribeiro R, Rubnitz J, Pui CH, Evans WE, Relling MV (2013) Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments. Cancer Chemother Pharmacol 72(2):369\u2013378. \n                    https:\/\/doi.org\/10.1007\/s00280-013-2206-x","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"3733_CR25","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/sj.leu.2401673","volume":"14","author":"AM Wall","year":"2000","unstructured":"Wall AM, Gajjar A, Link A, Mahmoud H, Pui CH, Relling MV (2000) Individualized methotrexate dosing in children with relapsed acute lymphoblastic leukemia. Leukemia 14(2):221\u2013225","journal-title":"Leukemia"},{"issue":"12","key":"3733_CR26","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.2165\/00003088-200645120-00007","volume":"5","author":"D Aumente","year":"2006","unstructured":"Aumente D, Buelga DS, Lukas JC, Gomez P, Torres A, Garcia MJ (2006) Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia. Clin Pharmacokinetics 5(12):1227\u20131238. \n                    https:\/\/doi.org\/10.2165\/00003088-200645120-00007","journal-title":"Clin Pharmacokinetics"},{"key":"3733_CR27","unstructured":"Common terminology criteria for adverse events v4.03 NIH publication # 09-7473. \n                    http:\/\/ctep.cancer.gov"},{"issue":"1","key":"3733_CR28","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/MPH.0000000000000696","volume":"39","author":"JH Foster","year":"2017","unstructured":"Foster JH, Bernhardt MB, Thompson PA, Smith EO, Schafer ES (2017) Using a bedside algorithm to individually dose high-dose methotrexate for patients at risk for toxicity. J Pediatr Hematol Oncol 39(1):72\u201376. \n                    https:\/\/doi.org\/10.1097\/MPH.0000000000000696","journal-title":"J Pediatr Hematol Oncol"},{"key":"3733_CR29","first-page":"62","volume-title":"Concepts in clinical pharmacokinetics","author":"J DiPiro","year":"2010","unstructured":"DiPiro J, Spruill W, Wade W, Blouin R, Pruemer J (2010) Concepts in clinical pharmacokinetics, 5th\u00a0edn. American Society of Health-System Pharmacists, Bethesda, pp\u00a062\u201364","edition":"5"},{"issue":"6","key":"3733_CR30","doi-asserted-by":"publisher","first-page":"e231","DOI":"10.1016\/S1470-2045(16)30035-3","volume":"17","author":"K Schmiegelow","year":"2016","unstructured":"Schmiegelow K, Attarbaschi A, Barzilai S, Escherich G, Frandsen TL, Halsey C, Hough R, Jeha S, Kato M, Liang DC, Mikkelsen TS, Moricke A, Niinimaki R, Piette C, Putti MC, Raetz E, Silverman LB, Skinner R, Tuckuviene R, van der Sluis I, Zapotocka E, Ponte di Legno toxicity working g (2016) Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus. Lancet Oncol 17(6):e231\u2013e239. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(16)30035-3","journal-title":"Lancet Oncol"},{"issue":"1","key":"3733_CR31","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/ki.2013.444","volume":"85","author":"A Levin","year":"2014","unstructured":"Levin A, Stevens PE (2014) Summary of KDIGO 2012 CKD guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney Int 85(1):49\u201361. \n                    https:\/\/doi.org\/10.1038\/ki.2013.444","journal-title":"Kidney Int"},{"issue":"10","key":"3733_CR32","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/sj.ki.5002231","volume":"71","author":"A Akcan-Arikan","year":"2007","unstructured":"Akcan-Arikan A, Zappitelli M, Loftis LL, Washburn KK, Jefferson LS, Goldstein SL (2007) Modified RIFLE criteria in critically ill children with acute kidney injury. Kidney Int 71(10):1028\u20131035. \n                    https:\/\/doi.org\/10.1038\/sj.ki.5002231","journal-title":"Kidney Int"},{"issue":"17","key":"3733_CR33","doi-asserted-by":"publisher","first-page":"4321","DOI":"10.1002\/cncr.27378","volume":"118","author":"AM Christensen","year":"2012","unstructured":"Christensen AM, Pauley JL, Molinelli AR, Panetta JC, Ward DA, Stewart CF, Hoffman JM, Howard SC, Pui CH, Pappo AS, Relling MV, Crews KR (2012) Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients. Cancer 118(17):4321\u20134330. \n                    https:\/\/doi.org\/10.1002\/cncr.27378","journal-title":"Cancer"},{"key":"3733_CR34","first-page":"81","volume":"5","author":"WE Evans","year":"1987","unstructured":"Evans WE, Abromowitch M, Crom WR, Relling MV, Bowman WP, Pui CH, Ochs J, Dodge R (1987) Clinical pharmacodynamic studies of high-dose methotrexate in acute lymphocytic leukemia. NCI Monogr 5:81\u201385","journal-title":"NCI Monogr"},{"issue":"1","key":"3733_CR35","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1097\/MPH.0b013e31820ee239","volume":"34","author":"WL Salzer","year":"2012","unstructured":"Salzer WL, Winick NJ, Wacker P, Lu X, Devidas M, Shuster JJ, Mahoney DH, Lauer SJ, Camitta BM (2012) Plasma methotrexate, red blood cell methotrexate, and red blood cell folate values and outcome in children with precursor B-acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group. J Pediatr Hematol Oncol 34(1):e1\u2013e7. \n                    https:\/\/doi.org\/10.1097\/MPH.0b013e31820ee239","journal-title":"J Pediatr Hematol Oncol"},{"issue":"8","key":"3733_CR36","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1056\/NEJM199802193380803","volume":"338","author":"WE Evans","year":"1998","unstructured":"Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH (1998) Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 338(8):499\u2013505. \n                    https:\/\/doi.org\/10.1056\/NEJM199802193380803","journal-title":"N Engl J Med"},{"issue":"5","key":"3733_CR37","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/j.1600-0609.2008.01128.x","volume":"81","author":"PB van Kooten Niekerk","year":"2008","unstructured":"van Kooten Niekerk PB, Schmiegelow K, Schroeder H (2008) Influence of methylene tetrahydrofolate reductase polymorphisms and coadministration of antimetabolites on toxicity after high dose methotrexate. Eur J Haematol 81(5):391\u2013398. \n                    https:\/\/doi.org\/10.1111\/j.1600-0609.2008.01128.x","journal-title":"Eur J Haematol"},{"issue":"4","key":"3733_CR38","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/pbc.25850","volume":"63","author":"C Badke","year":"2016","unstructured":"Badke C, Fleming A, Iqbal A, Khilji O, Parhas S, Weinstein J, Morgan E, Hijiya N (2016) Rechallenging with intrathecal methotrexate after developing subacute neurotoxicity in children with hematologic malignancies. Pediatr Blood Cancer 63(4):723\u2013726. \n                    https:\/\/doi.org\/10.1002\/pbc.25850","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"3733_CR39","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1200\/JCO.2013.53.0808","volume":"32","author":"D Bhojwani","year":"2014","unstructured":"Bhojwani D, Sabin ND, Pei D, Yang JJ, Khan RB, Panetta JC, Krull KR, Inaba H, Rubnitz JE, Metzger ML, Howard SC, Ribeiro RC, Cheng C, Reddick WE, Jeha S, Sandlund JT, Evans WE, Pui CH, Relling MV (2014) Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol 32(9):949\u2013959. \n                    https:\/\/doi.org\/10.1200\/JCO.2013.53.0808","journal-title":"J Clin Oncol"},{"key":"3733_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26395","author":"T Svahn","year":"2017","unstructured":"Svahn T, Mellgren K, Harila-Saari A, Asberg A, Kanerva J, Jonsson O, Vaitkeviciene G, Stamm Mikkelssen T, Schmiegelow K, Heldrup J (2017) Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia. Pediatr Blood Cancer. \n                    https:\/\/doi.org\/10.1002\/pbc.26395","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"3733_CR41","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/ng0595-111","volume":"10","author":"P Frosst","year":"1995","unstructured":"Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP et al (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10(1):111\u2013113. \n                    https:\/\/doi.org\/10.1038\/ng0595-111","journal-title":"Nat Genet"},{"key":"3733_CR42","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/69802","author":"LB Mahmoud","year":"2018","unstructured":"Mahmoud LB, Mdhaffar M, Frikha R, Ghozzi H, Hakim A, Sahnoun Z, Elloumi M, Zeghal K (2018) Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia. Adv Clin Exp Med. \n                    https:\/\/doi.org\/10.17219\/acem\/69802","journal-title":"Adv Clin Exp Med"},{"issue":"6","key":"3733_CR43","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/tpj.2012.44","volume":"13","author":"E Lopez-Lopez","year":"2013","unstructured":"Lopez-Lopez E, Martin-Guerrero I, Ballesteros J, Garcia-Orad A (2013) A systematic review and meta-analysis of MTHFR polymorphisms in methotrexate toxicity prediction in pediatric acute lymphoblastic leukemia. Pharmacogenomics J 13(6):498\u2013506. \n                    https:\/\/doi.org\/10.1038\/tpj.2012.44","journal-title":"Pharmacogenomics J"},{"issue":"6","key":"3733_CR44","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1080\/10428190902893819","volume":"50","author":"M Kantar","year":"2009","unstructured":"Kantar M, Kosova B, Cetingul N, Gumus S, Toroslu E, Zafer N, Topcuoglu N, Aksoylar S, Cinar M, Tetik A, Eroglu Z (2009) Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Leuk Lymphoma 50(6):912\u2013917. \n                    https:\/\/doi.org\/10.1080\/10428190902893819","journal-title":"Leuk Lymphoma"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-018-3733-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3733-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3733-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T07:34:50Z","timestamp":1589614490000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-018-3733-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,28]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["3733"],"URL":"https:\/\/doi.org\/10.1007\/s00280-018-3733-2","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,28]]},"assertion":[{"value":"13 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"No authors have any conflicts of interest to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}